Inovio Pharmaceuticals Inc. (INO)

2.82
NASDAQ : Health Technology
Prev Close 2.79
Day Low/High 2.77 / 2.86
52 Wk Low/High 2.15 / 6.30
Avg Volume 1.03M
Exchange NASDAQ
Shares Outstanding 98.03M
Market Cap 273.51M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Inovio Completes Enrollment Of VGX-3100 Phase 2 Trial For The Treatment Of HPV-Related Vulvar Dysplasia (VIN)

Inovio Completes Enrollment Of VGX-3100 Phase 2 Trial For The Treatment Of HPV-Related Vulvar Dysplasia (VIN)

Biotech company will report interim data later this year

Inovio Completes Enrollment Of VGX-3100 Phase 3 Trial (REVEAL 1) For The Treatment Of HPV-Related Cervical Pre-cancer

Inovio Completes Enrollment Of VGX-3100 Phase 3 Trial (REVEAL 1) For The Treatment Of HPV-Related Cervical Pre-cancer

PLYMOUTH MEETING, Pa., June 26, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Inovio Receives $8.14 Million Award To Support Further Development Of Its Commercial Skin Delivery Device

Inovio Receives $8.14 Million Award To Support Further Development Of Its Commercial Skin Delivery Device

PLYMOUTH MEETING, Pa., June 10, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Inovio First To Advance Lassa Fever Candidate Vaccine Into A Clinical Trial

Inovio First To Advance Lassa Fever Candidate Vaccine Into A Clinical Trial

Subjects dosed in First-in-Human study of INO-4500 funded by the Coalition for Epidemic Preparedness Innovations

Inovio And QIAGEN Establish Collaboration To Develop Diagnostic Test For VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer

Inovio And QIAGEN Establish Collaboration To Develop Diagnostic Test For VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer

Liquid biopsy-based Precision Medicine test to guide patient selection for Inovio's VGX-3100

Inovio And Plumbline Life Sciences Establish Animal Health Collaboration To Develop A Novel Vaccine Against Deadly African Swine Fever Virus

Inovio And Plumbline Life Sciences Establish Animal Health Collaboration To Develop A Novel Vaccine Against Deadly African Swine Fever Virus

PLYMOUTH MEETING, Pa. and SEOUL, South Korea, May 15, 2019 /PRNewswire/ -- Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Reports 2019 First Quarter Financial Results

Inovio Pharmaceuticals Reports 2019 First Quarter Financial Results

PLYMOUTH MEETING, Pa., May 9, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Inovio Receives European Medicines Agency Certification For Quality And Non-Clinical Data For Its Phase 3 Product, VGX-3100

Inovio Receives European Medicines Agency Certification For Quality And Non-Clinical Data For Its Phase 3 Product, VGX-3100

PLYMOUTH MEETING, Pa., May 6, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals To Report First Quarter 2019 Financial Results On May 9, 2019

Inovio Pharmaceuticals To Report First Quarter 2019 Financial Results On May 9, 2019

PLYMOUTH MEETING, Pa., May 1, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

First Week Of June 21st Options Trading For Inovio Pharmaceuticals (INO)

First Week Of June 21st Options Trading For Inovio Pharmaceuticals (INO)

Investors in Inovio Pharmaceuticals Inc. saw new options become available this week, for the June 21st expiration.

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

Inovio's Phase 3 HPV Immunotherapy Selected As "Best Therapeutic Vaccine" At World Vaccine Congress

Inovio's Phase 3 HPV Immunotherapy Selected As "Best Therapeutic Vaccine" At World Vaccine Congress

PLYMOUTH MEETING, Pa., April 17, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Aerie and Inovio Among Pharma Stocks Offering High Risk and Even Higher Upside

Aerie and Inovio Among Pharma Stocks Offering High Risk and Even Higher Upside

Risk and reward are the yin and yang of investing, and are closely related, especially in the pharmaceutical field.

Inovio Achieves Third Cancer Indication Milestone For MEDI0457 Phase 2 Development

Inovio Achieves Third Cancer Indication Milestone For MEDI0457 Phase 2 Development

PLYMOUTH MEETING, Pa., April 8, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Inovio's Novel HPV Therapy INO-3106 Demonstrates Clinical Efficacy Against Rare Respiratory Tract Tumors In Pilot Clinical Study

Inovio's Novel HPV Therapy INO-3106 Demonstrates Clinical Efficacy Against Rare Respiratory Tract Tumors In Pilot Clinical Study

Clinical Data Presented at Annual Meeting of American Association for Cancer Research

Inovio Presents Cancer Killing Data Of Its Transformative DNA-Encoded Bi-specific T Cell Engagers (dBiTEs) At AACR

Inovio Presents Cancer Killing Data Of Its Transformative DNA-Encoded Bi-specific T Cell Engagers (dBiTEs) At AACR

Data demonstrates tumor-clearing ability of Inovio's dBiTE technology in preclinical cancer model

Inovio Completes Enrollment Ahead Of Schedule In Immuno-Oncology Study For Glioblastoma (GBM) With INO-5401 In Combination With Regeneron's PD-1 Inhibitor

Inovio Completes Enrollment Ahead Of Schedule In Immuno-Oncology Study For Glioblastoma (GBM) With INO-5401 In Combination With Regeneron's PD-1 Inhibitor

PLYMOUTH MEETING, Pa., April 1, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals To Present At H.C. Wainwright Global Life Sciences Conference In London, UK

Inovio Pharmaceuticals To Present At H.C. Wainwright Global Life Sciences Conference In London, UK

PLYMOUTH MEETING, Pa., March 27, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Inovio Appoints Global Commercial Leader To Its Board Of Directors

Inovio Appoints Global Commercial Leader To Its Board Of Directors

PLYMOUTH MEETING, Pa., March 25, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

First Week Of INO November 15th Options Trading

First Week Of INO November 15th Options Trading

Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the November 15th expiration.

Inovio Pharmaceuticals Reports 2018 Fourth Quarter And Year-End Financial Results

Inovio Pharmaceuticals Reports 2018 Fourth Quarter And Year-End Financial Results

PLYMOUTH MEETING, Pa., March 12, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Inovio Appoints Chief Operating Officer; Announces Strategic Management Changes

Inovio Appoints Chief Operating Officer; Announces Strategic Management Changes

PLYMOUTH MEETING, Pa., March 12, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals To Announce Fourth Quarter And Full Year 2018 Financial Results And Host Conference Call On March 12, 2019

Inovio Pharmaceuticals To Announce Fourth Quarter And Full Year 2018 Financial Results And Host Conference Call On March 12, 2019

PLYMOUTH MEETING, Pa., March 5, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Inovio Initiates REVEAL 2 Global Phase 3 Clinical Study For The Treatment Of HPV-Related Cervical Pre-cancer

Inovio Initiates REVEAL 2 Global Phase 3 Clinical Study For The Treatment Of HPV-Related Cervical Pre-cancer

The second Phase 3 study initiation announcement made during the International HPV Awareness Day

Inovio Pharmaceuticals Completes Sale Of Additional Convertible Senior Notes

Inovio Pharmaceuticals Completes Sale Of Additional Convertible Senior Notes

PLYMOUTH MEETING, Pa., March 1, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.

Geneos Therapeutics Secures $10.5 Million In Series A Financing To Develop The Next Generation Of Neoantigen-Targeting Cancer Immunotherapies

Geneos Therapeutics Secures $10.5 Million In Series A Financing To Develop The Next Generation Of Neoantigen-Targeting Cancer Immunotherapies

Geneos has Licensed Immunotherapy Platform from Inovio Pharmaceuticals for Developing Personalized Cancer Treatments

TheStreet Quant Rating: D (Sell)